Hodgkin's lymphoma is one of the more curable cancers. About 75% of patients are cured by initial therapy.
However, for those failed by chemotherapy, there is no standard therapy. New drugs moving through clinical trials at MD Anderson appear to provide an answer for resistant or relapsed Hodgkin's lymphoma.
Two MD Anderson patients and two oncologists from the Department of Lymphoma/Myeloma talk about the latest developments at Patient Power
Breakthroughs in Lymphoma from Patient Power® on Vimeo.
Follow Dr. Younes on Twitter
Doctors, Patients Discuss New Hope for Relapsed Hodgkin's Lymphoma
- Global Navigation
- About Us
- Locations
- Calendar
- Careers
- How You Can Help
- Children's Art Project
- Directory
- Contact Us
- Sitemap
- Patient and Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children’s Cancer Hospital
- Services & Amenities
- Clinical Trials
- News and Publications
- Newsroom
- Publications
- Education and Research
- Departments, Programs & Labs
- Research at MD Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates
- State of Texas
- State of Texas Home Page
- Statewide Search (TRAIL)
- State Comptroller - Where the Money Goes
- Texas Homeland Security
- The University of Texas System
- Institution Resume
- Legal and Policy
- Legal Statements & Site Policies
- Stay Connected
- Emergency Alerts
- Emergency Alert Information
© 2013 The University of Texas MD Anderson Cancer Center
Leave a comment